Study analysis · Pakistan Journal of Physiology · 2024
Older, heavier men have 54% less testosterone—and this hormone surge might be why.
As men get older or gain weight, their testosterone drops and another hormone called adiponectin goes up—and they’re strongly linked.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at a group of men once and found that older and heavier men tended to have less testosterone and more adiponectin. But it didn't watch them over time, so we can't say if being heavier made testosterone drop, or if low testosterone made people gain weight — it just shows they often happen together.
What’s the bottom line?
As men get older or gain weight, their testosterone (a key male hormone) goes down, while adiponectin (a fat-related hormone) goes up — and they seem to be linked.
How strong is this study?
The study measured hormones carefully and grouped men fairly, which is good. But it didn't control for things like diet or exercise, and it only checked once — so while the numbers look real, we can't be sure why they're that way. That's why we should be careful not to say one thing causes another.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
27 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=80)+6.6/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 543 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a cross-sectional study that measures variables at a single point in time, so it cannot determine whether changes in testosterone cause changes in adiponectin or vice versa. Temporal sequence and control of confounders are not established.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study. All authors appear to be affiliated with academic institutions without industry ties.
The study uses commercially available ELISA kits from ASTRA BIOTECH (Germany) and AviBion (Finland), but there is no disclosure of funding, author affiliation with these companies, or involvement in study design or analysis. All authors are affiliated with academic medical institutions in Pakistan. No industry funding or conflict of interest is indicated.
Key takeaways
- 01
Testosterone dropped by about 54% from young non-obese to elderly obese men.
- 02
Adiponectin was highest in elderly obese men.
- 03
Testosterone and adiponectin always moved in opposite directions.
- 04
Yes — lower testosterone and higher adiponectin in older, obese men may increase risk for metabolic problems like diabetes or heart disease.
Surprising findings
- Adiponectin levels were higher in obese men—even though most prior research says adiponectin drops with obesity.Most studies link obesity with lower adiponectin, but this study found the opposite in healthy men—suggesting that in the absence of diabetes or inflammation, obesity may actually raise adiponectin when testosterone is low.
- No significant difference in testosterone between older obese and older non-obese men.You’d expect obese older men to have the lowest testosterone—but the study found no significant difference between older obese and older non-obese men (p=0.114), suggesting aging alone may be the dominant driver.
Practical takeaways
If you're a man over 40 and gaining weight, get your testosterone checked—not just for libido, but for energy, muscle retention, and metabolic health.
This study can't prove causation—low testosterone might be a result, not a cause, of aging and obesity.
medium confidenceFocus on losing belly fat—even modest weight loss can help restore testosterone and break the adiponectin feedback loop.
Testosterone replacement isn't a magic fix—lifestyle changes are still the foundation.
medium confidenceWhy this study matters
Testosterone Plummets 54% in Older Obese Men
Testosterone levels in elderly obese men were 54% lower than in young non-obese men (680 ng/dL vs. 258 ng/dL), according to ELISA measurements. This drop was statistically significant (p=0.00) and most extreme in the oldest, heaviest group.
This isn't just 'getting older'—it's the combo of aging and obesity that crushes testosterone, which affects energy, muscle, mood, and even heart health.
Adiponectin Rises—But It’s Not the 'Good Hormone' Here
Adiponectin, often called a 'healthy fat hormone,' was highest in elderly obese men (41.15 μg/mL), nearly double that of young non-obese men (21.1 μg/mL). But in this context, its rise correlates with low testosterone and metabolic risk.
It flips the script: what we think of as a 'good' hormone might actually be a red flag when it spikes alongside low testosterone in aging men.
Testosterone and Adiponectin Are Inversely Linked—Stronger in Older Men
The study found a strong negative correlation (rho = -0.813) between testosterone and adiponectin in older non-obese men, and -0.718 in older obese men. This link was stronger than in younger men (rho = -0.517).
It’s not just that both change with age—aging makes their inverse relationship tighter, suggesting a biological feedback loop that worsens over time.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
As men get older or gain weight, their testosterone (a key male hormone) goes down, while adiponectin (a fat-related hormone) goes up — and they seem to be linked.
Research results
Testosterone dropped by about 54% from young non-obese to elderly obese men. Adiponectin was highest in elderly obese men. Testosterone and adiponectin always moved in opposite directions.
What this means - more context
Yes — lower testosterone and higher adiponectin in older, obese men may increase risk for metabolic problems like diabetes or heart disease.
This study investigates how aging and obesity affect serum testosterone and adiponectin levels in healthy men.
Testosterone levels decline significantly with both aging and obesity, while adiponectin levels rise, with the most pronounced changes in older obese men. A strong negative correlation exists between testosterone and adiponectin, especially in older and obese groups.
Methods Used
Cross-sectional study of 80 healthy males divided into four groups (young/non-obese, young/obese, elderly/non-obese, elderly/obese). Serum testosterone and adiponectin were measured using ELISA. Statistical analysis included Mann-Whitney U, ANOVA, Tukey’s post hoc, and Spearman’s correlation.
Main Finding
Testosterone levels were 54% lower in elderly obese men compared to young non-obese men (p=0.00); adiponectin levels were highest in elderly obese men. A significant negative correlation between testosterone and adiponectin was found across all subgroups (rho = -0.444 to -0.813, p≤0.001).
Confidence Level
Moderate — findings are statistically significant within the sample, but single-time measurement, small sample size, and lack of effect sizes or confidence intervals limit generalizability.
Study Flags
Red Flags
- •Cross-sectional design (cannot prove causation)
- •Small sample size (n=80)
- •No effect sizes or confidence intervals reported
Surprising Findings
Adiponectin levels were higher in obese men—even though most prior research says adiponectin drops with obesity.
Most studies link obesity with lower adiponectin, but this study found the opposite in healthy men—suggesting that in the absence of diabetes or inflammation, obesity may actually raise adiponectin when testosterone is low.
Practical Takeaways
If you're a man over 40 and gaining weight, get your testosterone checked—not just for libido, but for energy, muscle retention, and metabolic health.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 543 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study looked at a group of men once and found that older and heavier men tended to have less testosterone and more adiponectin. But it didn't watch them over time, so we can't say if being heavier made testosterone drop, or if low testosterone made people gain weight — it just shows they often happen together.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear subgroup stratification by age and obesity status
- Use of validated ELISA kits with high specificity and precision for hormone measurement
- Standardized anthropometric measurements following WHO guidelines
Weaknesses
- Cross-sectional design prevents determination of temporal sequence or causality
- Blinding status unknown, risking measurement bias
- Single time-point measurement cannot capture dynamic hormonal changes
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
As men get older or gain weight, their testosterone (a key male hormone) goes down, while adiponectin (a fat-related hormone) goes up — and they seem to be linked.
Research results
Testosterone dropped by about 54% from young non-obese to elderly obese men. Adiponectin was highest in elderly obese men. Testosterone and adiponectin always moved in opposite directions.
What this means - more context
Yes — lower testosterone and higher adiponectin in older, obese men may increase risk for metabolic problems like diabetes or heart disease.
This study investigates how aging and obesity affect serum testosterone and adiponectin levels in healthy men.
Testosterone levels decline significantly with both aging and obesity, while adiponectin levels rise, with the most pronounced changes in older obese men. A strong negative correlation exists between testosterone and adiponectin, especially in older and obese groups.
Methods Used
Cross-sectional study of 80 healthy males divided into four groups (young/non-obese, young/obese, elderly/non-obese, elderly/obese). Serum testosterone and adiponectin were measured using ELISA. Statistical analysis included Mann-Whitney U, ANOVA, Tukey’s post hoc, and Spearman’s correlation.
Main Finding
Testosterone levels were 54% lower in elderly obese men compared to young non-obese men (p=0.00); adiponectin levels were highest in elderly obese men. A significant negative correlation between testosterone and adiponectin was found across all subgroups (rho = -0.444 to -0.813, p≤0.001).
Confidence Level
Moderate — findings are statistically significant within the sample, but single-time measurement, small sample size, and lack of effect sizes or confidence intervals limit generalizability.
Study Flags
Red Flags
- •Cross-sectional design (cannot prove causation)
- •Small sample size (n=80)
- •No effect sizes or confidence intervals reported
Surprising Findings
Adiponectin levels were higher in obese men—even though most prior research says adiponectin drops with obesity.
Most studies link obesity with lower adiponectin, but this study found the opposite in healthy men—suggesting that in the absence of diabetes or inflammation, obesity may actually raise adiponectin when testosterone is low.
Practical Takeaways
If you're a man over 40 and gaining weight, get your testosterone checked—not just for libido, but for energy, muscle retention, and metabolic health.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 543 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study looked at a group of men once and found that older and heavier men tended to have less testosterone and more adiponectin. But it didn't watch them over time, so we can't say if being heavier made testosterone drop, or if low testosterone made people gain weight — it just shows they often happen together.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear subgroup stratification by age and obesity status
- Use of validated ELISA kits with high specificity and precision for hormone measurement
- Standardized anthropometric measurements following WHO guidelines
Weaknesses
- Cross-sectional design prevents determination of temporal sequence or causality
- Blinding status unknown, risking measurement bias
- Single time-point measurement cannot capture dynamic hormonal changes
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study measured hormones carefully and grouped men fairly, which is good. But it didn't control for things like diet or exercise, and it only checked once — so while the numbers look real, we can't be sure why they're that way. That's why we should be careful not to say one thing causes another.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
27 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=80)+6.6/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 543 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a cross-sectional study that measures variables at a single point in time, so it cannot determine whether changes in testosterone cause changes in adiponectin or vice versa. Temporal sequence and control of confounders are not established.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study. All authors appear to be affiliated with academic institutions without industry ties.
The study uses commercially available ELISA kits from ASTRA BIOTECH (Germany) and AviBion (Finland), but there is no disclosure of funding, author affiliation with these companies, or involvement in study design or analysis. All authors are affiliated with academic medical institutions in Pakistan. No industry funding or conflict of interest is indicated.